By comparing the significance of ApoB in breast cancer patients, benign breast tumor patients, and the combined patient group [15], as well as assessing the impact of the history of breast cancer on myocardial ischemia occurrence, we observed that ApoB was a more crucial predictor of myocardial ischemia in breast cancer patients compared to those with benign breast tumors. Here, APOB is linked to breast carcinoma.